Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | ST6GAL1 | P15907 | 7/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694099 | 0.88 | POLA1 (0.37) | POLA1TSHRGLAST6GAL1P2RY2 | |
| SCHEMBL5694132 | 0.83 | ADORA1 (0.42) | P2RY2 | |
| SCHEMBL5694113 | 0.81 | POLB (0.42) | POLA1ST6GAL1P2RY2LMNAPOLB | |
| SCHEMBL5908145 | 0.80 | ST6GAL1 (0.39) | POLA1TSHRGLAST6GAL1P2RY2 | |
| SCHEMBL5694048 | 0.79 | P2RY6 (0.43) | P2RY2POLBP2RY6 | |
| SCHEMBL5908151 | 0.76 | P2RY6 (0.42) | ST6GAL1P2RY2POLBP2RY6 | |
| SCHEMBL5694075 | 0.73 | POLB (0.41) | POLA1ST6GAL1P2RY2POLBP2RY6 | |
| SCHEMBL5183563 | 0.72 | LMNA (0.34) | POLA1TSHRGLAST6GAL1LMNA | |
| SCHEMBL5694389 | 0.71 | DNMT1 (0.40) | LMNAMTORPOLB | |
| SCHEMBL13794604 | 0.71 | ALDH1A1 (0.45) | TSHRGLAST6GAL1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | POLA1 45/4885TSHR 1768/4885GLA 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.